SEC Form 4 · accession 0001140361-26-035610
Apogee Therapeutics, Inc. · APGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lisa Bollinger
Director
Period of report
Sep 3, 2026
Accepted (ET)
Sep 3, 2026 · 4:39 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001974640
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $47.86 | Sep 3, 2026 | D | 18,550 | D | — | May 28, 2034 | Common Stock | 18,550 | 0 | D |
| Stock Option (Right to Buy)F2,F1 | $43.85 | Sep 3, 2026 | D | 8,112 | D | — | Jun 5, 2034 | Common Stock | 8,112 | 0 | D |
| Stock Option (Right to Buy)F2,F1 | $41.66 | Sep 3, 2026 | D | 14,461 | D | — | Jun 17, 2035 | Common Stock | 14,461 | 0 | D |
| Stock Option (Right to Buy)F2,F1 | $85.00 | Sep 3, 2026 | D | 7,657 | D | — | Jun 9, 2036 | Common Stock | 7,657 | 0 | D |
Explanation of responses
- F1The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
- F2Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option.